The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
J. A. Chan
Research Funding - Novartis
D. P. Ryan
No relevant relationships to disclose
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AVEO; Bristol-Myers Squibb; Enzon; Genentech; Genomic Health; GlaxoSmithKline; ImClone Systems; Roche
A. X. Zhu
Consultant or Advisory Role - Novartis; Pfizer; Sanofi
Research Funding - Bayer
T. A. Abrams
No relevant relationships to disclose
B. M. Wolpin
Research Funding - Novartis
P. Malinowski
No relevant relationships to disclose
E. Regan
No relevant relationships to disclose
M. Kulke
Consultant or Advisory Role - Novartis
Research Funding - Novartis